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Classification 
- Two main entities may be distinguished within 
testicular germ-cell tumours: seminomas and non 
seminomatous germ-cell tumours (NSGCT). 
- Seminomas are composed of neoplastic germ cells. 
- Non seminomatous germ-cell tumours present 
multiple histologic subtypes with neoplastic 1- 
embryonic tissues (embryonal carcinoma, immature 
and mature teratoma), or 2- extraembryonic tissus (yolk 
sac tumour and choriocarcimoma), which are usually 
associated and are therefore called mixed germ cell 
tumours (the most frequent being teratocarcinoma). 
- There may been combined tumours of seminomatous 
and non seminomatous components. 
- Intratubular germ cell neoplasia (ITGCN), also called 
carcinoma in-situ, appears as a precursor lesion of 
invasive tumours (common precursor for both 
seminomas and NSGCT), but it can also be observed in 
patients without development of a testicular germ-cell 
tumour (GCT). 
- In adults, most testicular germ cell tumours are 
associated with ITGCN surrounding the invasive 
cancer. 
Clinics and pathology 
Disease 
Testicular germ-cell tumours (GCT) and intratubular 
germ cell neoplasia (ITGCN). 
Epidemiology 
Testicular tumours represent 1 to 2% of all malignant 
tumours in men; 30% of patient are < 35 yrs; 3 groups 
can be distinguished according to the age: (1) tumours 
of the infant, (2) tumours of the adolescent and young 
adult, (3) tumours of the elderly man; most yolk sac 
tumours occur in children < 2yrs; in young adults, 
tumours are seminomas in 50% of the cases and  
NSGCT in 40%; at presentation, patients with 
seminomas are generally older (med age 40 yrs) than 
those with NSGCT (med age 25 yrs). In the ederly 
persons, GCT are generaly seminoma (spermatocytic 
seminoma) or teratoma with malignant transformation. 
Clinics 
Germ cell tumours represent 95% of testicular cancers; 
cryptorchism is a great predisposing factor, as well as 
the occurrence of a seminoma in the controlateral tstis; 
a few cases have occurred in a familial setting; clinical 
presentation is generally a progressive and painless 
enlargement of the testis sometimes associated with 
gynecomastia. 
Pathology 
- Staging: the TNM (tumour/nodes/metastases) 
classification is the most used. The first parameter T 
ranges from pTis for ITGCN without associated GCT, 
to pT1 to pT4 for true GCT; a second classification 
commonly used by the urologists describes the tumour 
in 3 stages according to the limits of the tumour and the 
presence of lymph nodes invasion. 
- Immunohistochemistry: yolk sac tumours are 
associated with a hight level of a fœto-protein in the
peripheral blood; in choriocarcinomas, 
syncytiotrophoblastic cells (but not the 
cytotrophoblastic cells) have a ßHCG activity; ßHCG 
can also be mesured in seminomas with a 
syncytiotrophoblastic cells component, but placental 
alkalin phosphatase (PLAP) is more useful and specific 
(and also in ITGCN). 
Treatment 
The initial treatement in all cases is orchiectomy with 
high ligation of the spermatic cord; patients with 
classical seminoma receive thorough irradiation of the 
retroperitoneum; chemotherapy is given only to 
patients presenting with advanced disease; the 
treatement of stages I and II of NSGCT is controversal; 
orchiectomy may be followed by retroperitoneal
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lymphadenectomy, radiation therapy, and 
chemotherapy. 
Evolution 
A 2 yrs event free survival after therapy is associated 
with cure in 90% of cases. 
Prognosis 
According to the clinical stage and to the tumour 
histopathological type; seminomas limited to the testis 
(stage I) or with subdiaphragmatic lymph nodes (stage 
II) are cured in over 95% of cases; in NSGCT (exept 
choriocarcinomas) the overall cure rate is over 95% 
(40% to 95% in the case of metastases) but vary with
the histologic predominent subtype; embryonal 
carcinomas are associated with a poorer pronosis; 
choriocarcinomas bear a grave prognosis. 
Cytogenetics 
Cytogenetics, morphological 
i(12p) in 80% of cases. 
Probes 
According to some workers, D12Z3 gives a larger 
centromere signal in i(12p) than in normal 
chromosomes 12; for others who used the a-satellite 
sequence pa12H8 probe of the pericentrique zone of 
chromosome 12, no differences between normal 
chromosome 12 and i(12p) signals were found. In our 
experience, 12p anomalies can be hightly variable and 
we would be cautious concerning FISH image 
interpretation without a karyotype. 
Additional anomalies 
Chromosome mode is most often hypertriploid or 
tetraploidid in seminomas, and hypotetraploidy in 
nonseminomatous tumours. 
- The most frequent numerical anomalies are trisomy 
X, 7, 8 and 12, monosomy 11, 13 and 18. 
- Rearrangements in 1p23-36 and 7q11 regions are 
frequently associated with teratomas. 
- Anomalies in 1p22 region are found in cases of yolk 
sac tumours. 
- Duplications of the i(12p) occur during tumour 
evolution; it may be a prognosis factor: higher is the 
number of 12p copies higher appears to be the 
probability of therapy failure. 
- Loss of chromosome 15 is noted in association with 
nonseminomatous tumours and also in the CIS adjacent 
to these tumours. 
- The presence of hsr (homogeneously staining regions) 
and dmin (double minute) suggest amplifications of 
gene(s) during disease progression. 
Variants 
Other 12 chromosome anomalies leading to an increase 
in the number of 12p copies and a relative decrease in 
12q copies. 
Genes involved and Proteins 
Note: The genes involved are unknow. 
- Oncogene hypothesis: CGH (comparative genomic 
hybridization) and FISH using region specific probe 
delineated the amplified region in 12p11.2; the gene 
encoding the parathyroid hormone related peptide 
(mapped in 12p11) is a possible candidate. 
-Antioncogene hypothesis: loss of heterozygosity 
(LOH) studies showed a high incidence of LOH in the
12q13 and 12q22 regions suggesting presence of 
candidate tumour suppressor genes. 
To be noted 
It has been suggested by some authors that the i(12p) 
are formed by non reciprocal centromeric interchanges, 
while others argue that the occurrence of partial 
trisomies 12p through i(12p) or others anomalies of 12p 
derive from uniparental origin. 
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